Laboratorios Farmaceuticos Rovi, S.A. (BME: ROVI)

Market Cap	4.02B
Revenue (ttm)	778.00M
Net Income (ttm)	148.03M
Shares Out	51.15M
EPS (ttm)	2.79
PE Ratio	28.15
Forward PE	22.36
Dividend	1.10 (1.41%)
Ex-Dividend Date	Jul 8, 2024

Volume	24,047
Open	77.05
Previous Close	78.55
Day's Range	76.75 - 78.40
52-Week Range	46.78 - 94.80
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 1, 2024

About ROVI

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women’s health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Nepar...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1946
• Employees: 2,137
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2023, Fluidra's revenue was 2.11 billion, a decrease of -14.03% compared to the previous year's 2.45 billion. Earnings were 113.83 million, a decrease of -28.83%.